Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
07 Abril 2024 - 3:30PM
Business Wire
Edwards Lifesciences (NYSE: EW) announced the release of data
from the HUDDLE study that examined the prevalence of heart disease
and associated risk factors among members of the National Football
League (NFL) Alumni Association and their families. The findings of
this study, which identified a significant discrepancy between
participant self-awareness and actual prevalence of heart disease
and associated risk factors, were presented today during a
late-breaking clinical trials session at the American College of
Cardiology (ACC.24/WCC) and published simultaneously in The Journal
of the American College of Cardiology.
Results of the HUDDLE study indicated that the prevalence of
hypertension in the 498 screened participants was 83.8%, though
only about half (46.5%) self-reported a history of hypertension. Of
all participants screened and found to have an elevated systolic
blood pressure, a staggering 73.8% were also found to have
structural heart changes present on transthoracic echo sonography
(TTE).
“These alarming results are a call to action,” said Michael
Amponsah, MD, ChB, FACC, Interventional Cardiologist, Banner
Boswell Medical Center, Peoria, Ariz. “The disparities highlighted
in the cohort involved in the HUDDLE study point to a significant
opportunity to examine a greater role for routine age-based
screening, and especially for the expanded use of echocardiogram to
better identify undetected or undiagnosed heart disease and heart
failure.”
Initiated by Edwards in 2021, the HUDDLE study’s objective was
to examine the unrecognized prevalence of heart disease and
associated risk factors, particularly among groups historically
known to experience disparities in access to care. For instance,
with more than a million patients treated globally with TAVR, the
treatment rate of African Americans in the US has remained constant
over the past decade at around 4%, despite comprising approximately
14% of the US population.
Conducted across eight U.S. cities in cooperation with NFL
Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE
was a cross sectional study of NFL alumni and their family members
aged 50 years and above. The participants were mostly male (66.5%)
and African American or Black (63%). Study participants
self-reported their medical histories and participated in heart
health education and screenings that included blood pressure,
electrocardiogram (EKG) and echocardiogram.
“Edwards is committed to helping identify and dismantle barriers
to access for communities that are underserved due to race, gender
and socioeconomic status,” said Larry Wood, Edwards’ corporate vice
president and group president, transcatheter aortic valve
replacement and surgical structural heart. “We realized that by
working with the NFL Alumni Association and through this unique
network of former players, we might be able to gain a greater
understanding of how heart disease is impacting underserved
populations, and how education, awareness and simple screening
tools can save lives in these communities and in the entire nation
as a whole.”
About Edwards
Lifesciences
Edwards Lifesciences is the global leader of patient-focused
innovations for structural heart disease and critical care
monitoring. We are driven by a passion for patients, dedicated to
improving and enhancing lives through partnerships with clinicians
and stakeholders across the global healthcare landscape. For more
information, visit Edwards.com and follow us on Facebook,
Instagram, LinkedIn, Twitter and YouTube.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
We intend the forward-looking statements contained in this Proxy
Statement to be covered by the safe harbor provisions of such Acts.
These forward-looking statements can sometimes be identified by the
use of forward-looking words, such as “may,” “might,” “believe,”
“will,” “expect,” “project,” “estimate,” “should,” “anticipate,”
“plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,”
“aspire,” “confident” and other forms of these words and include,
but are not limited to, statements made by Mr. Wood and statements
regarding expected product benefits, patient outcomes,
post-treatment reduction of invasive procedures, objectives and
expectations and other statements that are not historical facts.
Forward-looking statements are based on estimates and assumptions
made by management of the company and are believed to be
reasonable, though they are inherently uncertain and difficult to
predict. Our forward-looking statements speak only as of the date
on which they are made, and we do not undertake any obligation to
update any forward-looking statement to reflect events or
circumstances after the date of the statement. Investors are
cautioned not to unduly rely on such forward-looking
statements.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors as detailed in the company's filings with the Securities
and Exchange Commission. These filings, along with important safety
information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, and the stylized E logo are
trademarks of Edwards Lifesciences Corporation. All other
trademarks are the property of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240407981063/en/
Media Contact: Howard Wright, 949-250-2790 Investor Contact:
Mark Wilterding, 949-250-6826
Edwards Lifesciences (NYSE:EW)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Edwards Lifesciences (NYSE:EW)
Gráfica de Acción Histórica
De May 2023 a May 2024